234 results
424B3
SNOA
Sonoma Pharmaceuticals Inc.
8 Mar 24
Prospectus supplement
4:27pm
a material adverse effect on our access to capital markets, and any limitation on market liquidity or reduction in the price of its common stock
8-K
EX-10.1
SNOA
Sonoma Pharmaceuticals Inc.
9 Jan 24
Entry into a Material Definitive Agreement
4:47pm
. In connection with this Agreement each Party may gain access to certain confidential and proprietary information of the other Party, which will be deemed
8-K
EX-1.1
SNOA
Sonoma Pharmaceuticals Inc.
15 Dec 23
Entry into a Material Definitive Agreement
6:14pm
) access to assets is permitted only in accordance with management’s general or specific authorization; and (D) amounts reflected on the Company’s … and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification; (iii) the Company and the Subsidiaries have implemented
424B3
SNOA
Sonoma Pharmaceuticals Inc.
15 Dec 23
Prospectus supplement
5:30pm
of our common stock or warrants on Nasdaq. The delisting of our common stock and warrants from Nasdaq would have a material adverse effect on our access
424B5
lzh7atoq 8w3d645y
22 Nov 23
Prospectus supplement for primary offering
4:30pm
424B4
w5k1m66a4r61m
30 Oct 23
Prospectus supplement with pricing info
7:30am
8-K
EX-1.1
n8q6ndef4 ix40egw54
23 Dec 22
Entry into a Material Definitive Agreement
5:00pm